Dendritic Cell Derived‐Extracellular Vesicles Engineered to Express Interleukin‐12 and Anti‐CTLA‐4 on Their Surface for Combinational Cancer Immunotherapy
Journal of Extracellular Vesicles · 2025-04 · 14 (4)
DOI: 10.1002/jev2.70068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 16.04.2025. Verfasst von Jiangbin Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Hubei Province Clinical Research Center for Major Respiratory Diseases, and NHC Key Laboratory …. Hauptthemen laut MEDLINE: Interleukin-12, Dendritic Cells, Immunotherapy, Extracellular Vesicles. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Major Project, National Natural Science Foundation of China, the Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Dendritic cell (DC)‐derived extracellular vesicles (DEVs) are promising candidates for cancer vaccines, but their therapeutic effects still need further optimization. In this study, we utilized neoantigens, lipopolysaccharide and IFN‐γ to induce the maturation of DCs, and then isolated DEVs derived from these mature DCs. We showed that the immune checkpoint inhibitor (anti‐CTLA‐4 antibody, aCTLA‐4) can improve the immunostimulatory function of DEVs by directly activating T cells through immune checkpoint signal blockade. The cytokine interleukin‐12 (IL‐12), as one of the third signals for T cell activation, can also enhance the capability of DEVs to activate T cells directly. Based on these findings, we designed the engineered DEVs conjugated with IL‐12 and aCTLA‐4 (DEV@IL‐12‐aCTLA‐4) to improve the therapeutic potential of DEVs by providing sufficient immune regulatory signals. Moreover, the carrier property of DEVs also contributes to the delivery of IL‐12 and aCTLA‐4 to lymph nodes. This indicates that the conjugation of DEVs with IL‐12 and aCTLA‐4 constitutes a complementary approach, where IL‐12 and aCTLA‐4 help to enhance the T cell activation effect of DEVs, and DEVs facilitate the delivery of IL‐12 and aCTLA‐4. Our results showed that DEV@IL‐12‐aCTLA‐4 can enhance the Th1 immune response and reverse exhausted CD8 + T cells in the tumour microenvironment, effectively inducing robust T cell immune responses and inhibiting tumour growth in tumour‐bearing mice. Overall, this study expands the theoretical foundation of DEVs and provides a universal strategy for optimizing cancer combination immunotherapy by reprogramming DEVs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Hubei Province Clinical Research Center for Major Respiratory Diseases, and NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhon…
- Hubei Province Key Laboratory of Biological Targeted Therapy, MOE Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
ORCID-Profile: Mengfei Guo, Yang Jin
Förderung
- National Science and Technology Major Project
- National Natural Science Foundation of China
- the Ministry of Science and Technology of the People's Republic of China
- the National Key Research and Development Program of China
- Hubei Province Key Research and Development Project
- Joint Project Foundation of Jingshan Union Hospital of Huazhong University of Science and Technology
Zitieren
APA
Chen, J., Tan, Q., Yang, Z., Chen, W., Zhou, E., Li, M., Deng, J., Wu, Y., Liu, J., Xu, J., Guo, M., & Jin, Y. (2025). Dendritic Cell Derived‐Extracellular Vesicles Engineered to Express Interleukin‐12 and Anti‐CTLA‐4 on Their Surface for Combinational Cancer Immunotherapy. Journal of Extracellular Vesicles, 14(4). https://doi.org/10.1002/jev2.70068
Vancouver
Chen J, Tan Q, Yang Z, Chen W, Zhou E, Li M, et al. Dendritic Cell Derived‐Extracellular Vesicles Engineered to Express Interleukin‐12 and Anti‐CTLA‐4 on Their Surface for Combinational Cancer Immunotherapy. Journal of Extracellular Vesicles. 2025;14(4). doi:10.1002/jev2.70068
BibTeX
@article{Chen2025,
author = {Chen, Jiangbin and Tan, Qi and Yang, Zimo and Chen, Wenjuan and Zhou, E and Li, Minglei and Deng, Jingjing and Wu, Yali and Liu, Jiatong and Xu, Juanjuan and Guo, Mengfei and Jin, Yang},
title = {Dendritic Cell Derived‐Extracellular Vesicles Engineered to Express Interleukin‐12 and Anti‐CTLA‐4 on Their Surface for Combinational Cancer Immunotherapy},
journal = {Journal of Extracellular Vesicles},
year = {2025},
volume = {14},
number = {4},
doi = {10.1002/jev2.70068}
}
EUVIMED